Anti-infective Agents
Anti-infective Agents - Related Videos
06:56
An Assay for Quantifying Antibody-Mediated Phagocytosis of Parasite-Infected Erythrocytes
0 Views •
2025
This video demonstrates a flow cytometry-based phagocytosis assay involving labeled and opsonized Plasmodium falciparum-infected erythrocytes by monocytes. Flow cytometry identifies fluorescence in monocytes, confirming the successful identification of opsonized erythrocytes through phagocytosis.
05:35
An In Vitro Assay to Examine the Antibody-Dependent Enhancement of Viral Infection
0 Views •
2025
This video demonstrates an assay to measure antibody-dependent enhancement (ADE) of Dengue virus infection using Zika Virus Convalescent Serum. The assay uses Dengue reporter viral particles (RVPs) encoding a green fluorescent protein. Serum antibodies against the Zika Virus cross-react with RVPs to form a complex. The bound antibodies enhance RVP uptake by cells expressing the Fc receptor, which is detected using flow cytometry.
10:25
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
0 Views •
2021
The protocol described here outlines a fast and effective method for measuring neutralizing antibodies against the SARS-CoV-2 spike protein by evaluating the ability of convalescent serum samples to inhibit infection by an enhanced green fluorescent protein-labeled vesicular stomatitis virus pseudotyped with spike glycoprotein.
11:27
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
0 Views •
Cited by 5 •
2016
This protocol describes the preparation and characterization of a dendrimeric magnetic resonance imaging (MRI) contrast agent that carries cyclen-based macrocyclic chelates coordinating paramagnetic gadolinium ions. In a series of MRI experiments in vitro, this agent produced an amplified MRI signal when compared to the commercially available monomeric analogue.
07:40
Introducing Experimental Agents into the Mouse
0 Views •
2023
Many investigations performed in mice (Mus musculus) require the administration of an experimental agent to the animal. For example, it may be of interest to test the efficacy of a specific therapy, to induce a pathologic condition, or to administer anesthesia or palliative care. In order to ensure safe and efficient delivery, it is important to consider a variety of factors prior to the administration of the treatment. This video, which reviews agent administration in the mouse, begins by...
FAQs
Selective toxicity provides the therapeutic basis for targeting microorganisms while minimizing effects on host cells. The relevant pathogen processes include bacterial cell-wall synthesis, microbial protein or nucleic-acid production, fungal membrane integrity, and viral replication. In pharmacology, this principle helps explain how intended effects are achieved and why the biological target influences a drug’s safety profile.
Anti-infective agents are distinguished partly by the pathogen process they target. Antibacterial therapy may focus on cell-wall synthesis or microbial protein and nucleic-acid production, whereas antifungal therapy can affect membrane integrity and antiviral therapy can act on viral replication. These distinctions connect drug mechanism to organism type and help pharmacologists organize therapeutic options.
Resistance is important because it can alter whether an anti-infective agent remains effective against a microorganism. Pharmacology therefore examines both the causes and consequences of antimicrobial resistance rather than focusing only on immediate drug action. This perspective helps place treatment decisions within the broader problem of maintaining effective control of infectious disease.
Selection should begin with the causative microorganism and then account for the infection site, microbial susceptibility, and patient factors. These criteria connect the drug’s intended target with the clinical circumstances in which treatment is needed. Considering them together supports a more appropriate choice than selecting an agent based solely on its general antimicrobial category.
The infection site is one of the stated factors guiding anti-infective selection, alongside the causative organism, susceptibility, and patient characteristics. Its inclusion ensures that treatment decisions reflect where the infection is located rather than relying only on the microorganism involved. In pharmacology, this site-based consideration is part of matching therapy to the clinical situation.
Evaluation should include adverse effects and drug interactions in addition to antimicrobial activity. These considerations reveal how treatment may affect the patient and how one agent may alter the effects or behavior of another drug. Studying them alongside selective toxicity and patient factors provides a fuller basis for judging the suitability of an anti-infective therapy.